



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 747 048 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
11.12.1996 Bulletin 1996/50

(51) Int. Cl.⁶: **A61K 31/19, A61K 31/045,
A61K 35/78, A61K 31/015**

(21) Application number: 96109269.9

(22) Date of filing: 10.06.1996

(84) Designated Contracting States:
DE FR GB

(30) Priority: 09.06.1995 JP 143504/95
29.02.1996 JP 43029/96

(71) Applicant: Kabushiki Kaisha Yakurigaku Chuo
Kenkyusho
Tokyo 157 (JP)

(72) Inventors:
• Takahashi, Hidehiko
Tokyo 157 (JP)

• Hara, Susumu,
c/o K.K. Yakurigaku Chuo Kenkyusho
Tokyo 157 (JP)
• Matsui, Rieko,
c/o K.K. Yakurigaku Chuo Kenkyusho
Tokyo 157 (JP)

(74) Representative: Henkel, Feller, Hänzle & Partner
Möhlstrasse 37
81675 München (DE)

(54) **Diterpenes and flavonoids as 5-alpha-reductase inhibitors**

(57) Strong 5 α -reductase inhibitors are extracted and fractionated from Thuja orientalis and other similar crude drugs or they may be purified as diterpenes in isolated form. The inhibitors are used either on their own or as active ingredients of therapeutics in the treatment of diseases caused by the overactivity of 5 α -reductase or the hypersecretion of androgens, such as male pattern baldness, androgenetic alopecia, hirsutism, acne, prostatomegaly and cancer of the prostate.

EP 0 747 048 A2

Description

BACKGROUND OF THE INVENTION5 Field of the Invention

This invention relates to therapeutics of androgenetic diseases containing as active ingredients the nonsteroidal 5 α -reductase inhibitors that have been obtained by fractioning the extracts of crude drugs including Thuja orientalis, Fritillaria thunbergii, etc. The fractionated extracts of these crude drugs are directly used as therapeutics or they may be chromatographically or otherwise isolated and fixed as diterpenes which provide more potent therapeutics. The therapeutics of the invention exhibit pronounced efficacy against androgenetic diseases such as male pattern baldness, androgenetic alopecia, hirsutism, acne, prostatomegaly, and cancer of the prostate.

15 Prior Art

Androgenetic diseases including acne, seborrhea, male pattern baldness, androgenetic alopecia, hirsutism, prostatomegaly and cancer of the prostate are induced by excessive production of 5 α -dihydrotestosterone (DHT). Since the DHT is produced in a target organ by the reduction of androgens with 5 α -reductase, active efforts are being made to develop therapeutics of androgenetic diseases that contain 5 α -reductase inhibitors as active ingredients.

20 The 5 α -reductase inhibitors are known to be available as steroids and nonsteroids. Potent nonsteroids are far from being suitable for clinical application. Some of the steroidal 5 α -reductase inhibitors are at the advanced stage of commercialization but they cause the inevitable side effects of steroid hormones. Among the serious side effects caused by the steroid 5 α -reductase inhibitors are infectious diseases, peptic ulcer, diabetes, mental disorders, hypertension, withdrawal syndrome and adrenal insufficiency; the inhibitors also cause mild side effects such as moon face, obesity, acne, hirsutism, emmenopathy, edema, insomnia, osteoporosity and thrombosis. Steroids can cause not only the intended clinical effects but also unwanted side effects, so they are prescribed judiciously by physicians who administer the minimum necessary dose for the clinical efficacy while taking cautions to keep the possible side effects to minimal levels.

Crude drugs which are of plant origin are mostly low in side effects but very few of them have been found to exhibit pronounced efficacy against androgenetic diseases.


30 Under the circumstances, the present inventors conducted extensive studies in order to develop nonsteroidal substances that were potent 5 α -reductase inhibitors but which yet caused less side effects. The present inventors first discovered that a number of crude drugs had a 5 α -reductase inhibiting action in their extracts; they then isolated highly active substances from the extracts, fixed them and made further research for clinical applications of those substances.

35 SUMMARY OF THE INVENTION

In the course of their study, the present inventors discovered that the 5 α -reductase inhibitor contained in Thuja orientalis consisted of at least three components. Since two of the components (A and B) were contained in greater amounts and exhibited a higher inhibiting action than the other component (C), the present inventors first attempted to isolate A and B and analyze their structures. In a subsequent step, the inhibitor from component A was passed through a silica gel column and treated by preparative TLC on a thin layer coated with silver nitrate to isolate diterpenes; the inhibitor from component B was similarly treated to isolate flavonoids. The efficacy of the isolated diterpenes and flavonoids as inhibitors was examined by clinical tests. The inventors performed screening of the extracts of other crude drugs including Fritillaria thunbergii, Trachylobium verrucosum, Chromolaena collina, Abies sibirica, Mikania alvimii, and Nicotiana glauca and successfully isolated diterpenes that were nonsteroidal compounds, that had a strong 5 α -reductase inhibiting action and which yet caused limited side effects. The diterpenes and flavonoids could be used as therapeutics on their own or as active ingredients thereof in the treatment of diseases originating from the over activity of 5 α -reductase or the hypersecretion of androgens. The present invention has been accomplished on the basis of these findings.

50 Disclosure of the Diterpenes

The diterpenes isolated in the present invention have a double bond in the 12- and 14-positions, with the double bond in the 12-position taking the configuration E. Such diterpenes have the following skeletal structures:



Specific examples of these compounds are listed below:

- (E)-6-hydroxy-8(17),12,14-labdatrien-19-oic acid;
- (E)-8(17),12,14-labdatrien-18-oic acid;
- (E)-7-hydroxy-8(17),12,14-labdatrien-18-oic acid;
- (E)-12,14-labdadien-3,8-diol;
- (E)-12,14-labdadien-6,8-diol;
- (E)-12,14-labdadien-7,8-diol;
- (E)-12,14-labdadien-8,11-diol;
- (E)-12,14-labdadien-8,18-diol;
- (E)-12,14-labdadien-9,18-diol;
- (E)-12,14-labdadien-1,8,18-triol;
- (E)-12,14-labdadien-6,7,8-triol;
- (E)-12,14-labdadien-6,8,18-triol;
- (E)-12,14-labdadien-8-ol;
- (E)-8(17),12,14-labdatriene;
- (E)-7,12,14-labdatrien-6,17-diol;
- (E)-8(17),12,14-labdatrien-3,19-diol;
- (E)-8(17),12,14-labdatrien-18,19-diol;
- (E)-8(17),12,14-labdatrien-3-ol;
- (E)-8(17),12,14-labdatrien-7-ol; and
- (E)-8(17),12,14-labdatrien-19-ol.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph comparing the extracts of *Thuja orientalis* (components A, B and C) with the prior art steroids flutamide and cyproterone in terms of their activity of inhibiting 5 α -reductase; and

Fig. 2 is a graph comparing the extract (component A) of Thuja orientalis, the trans-communic acid isolated from component A and the prior art steroids flutamide and cyproterone in terms of their activity of inhibiting 5 α -reductase *in vitro*.

5 DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention will now be described with reference to its preferred embodiments.

Example 1

10

Substances capable of inhibiting 5 α -reductase may be extracted and fractionated by the following procedure.

A powder of Thuja orientalis is mixed with about 5 volumes of n-hexane and the mixture is heated under reflux and filtered. The solvent in the filtrate is distilled off under vacuum and the residue is dissolved in 60% ethanol which is about twice the amount of the starting Thuja orientalis powder. The undissolved portion is filtered off and the solvent

15 in the filtrate is distilled off under vacuum to yield a solid residue (component A).
The residue separated from the hexane extract is mixed with 60% ethanol which is about five times the amount of the starting Thuja orientalis powder and the mixture is heated under reflux and filtered. The solvent in the filtrate is distilled off under vacuum. To the residue, purified water is added in an amount about three times as much as the starting Thuja orientalis and the mixture is heated under reflux and filtered. The solvent in the residue is distilled off under

20 vacuum to yield a solid residue (component B) whereas the filtrate is recovered as component C.
This is not the only procedure for extracting and fractionating components A, B and C and the n-hexane may be replaced by other solvents such as petroleum ether, petroleum benzine and benzene. The described procedure is efficient and achieves high yield.

A flowchart of this process is set forth below in Table 1.

25

30

35


40

45

50

55

Table 1



Example 2

The activities of components A, B and C in inhibiting the 5 α -reductase prepared from the rat liver were measured. The method of preparing a crude 5 α -reductase solution is shown in Table 2 and an outline of the method for assaying the enzymatic activity is shown in Table 3. Flutamide and cyproterone were used as positive controls. The results of the measurements are shown graphically in Fig. 1, from which one can see that components A and B are effective 5 α -reductase inhibitors.

Table 2





Table 3

| 1) Reagent | Amount of addition, ml | Final concentration, mmol/L |
|--------------------------------------|------------------------|-----------------------------|
| 0.28 mM Testosterone (10% MeOH sol.) | 0.25 | 0.07 |
| 50 mM Tris-HCl sol. (pH 7.0) | 0.1 | 5.0 |
| 50 mM NADPH sol. | 0.1 | 5.0 |
| Sample (in 60% EOH) | 0.05 | - |
| Crude enzyme sol. | 0.025 | - |
| Purified water | 0.475 | - |
| To make | 1.0 | |
| Extractant: dichloromethane | 2.0 | |

2) Method



Example 3

Components A and B were isolated in pure form and analyzed for structure. Outlines of the methods for isolation are shown in Tables 4 and 5.

On the basis of $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, mass and IR spectral analyses, the active principle in component A as a 5α -reductase inhibitor was estimated to be a terpenoid and that in component B as a flavonoid.

Table 4





Table 5



Example 4

The 5 α -reductase inhibitors extracted from Thuja orientalis were examined for their efficacy against male pattern baldness in stage V. The test samples were components A, B and C, as well as the terpenoid isolated from component A and the (iso)scutellarein isolated from component B, which were each dissolved at a concentration of 1% in 50% alcohol. These samples were daily applied on a twice-a-day basis for a period of 4 months to the bald heads of 27 - 45 year old male volunteers in five groups each consisting of 5 cases. The test samples had no significant difference in therapeutic effects and all of them caused pronounced regrowth of hair. The extracts of Thuja orientalis were also examined for their efficacy against androgenic alopecia in women and there was found no significant difference by sex.

Example 5

Male hirsute volunteers (aged 25 - 40) had the hair in both inferior limbs depilated with wax in an area of 5 cm². To the depilated area of one inferior limb, component A, B, the terpenoid isolated from component A or the (iso)scutellarein isolated from component B that were dissolved at a concentration of 1% in 50% alcohol was applied. The depilated area of the other inferior limb was set aside as a control section and treated with 50% alcohol alone. Each volunteer group consisted of 5 cases. Regrowth of hair was significantly suppressed in the test sections as compared to the control section. When the experiment ended 3 months later, the control section was indistinguishable from the surrounding area but the regrowth of hair in the test sections was barely recognizable. There was also found no significant difference in efficacy among the test samples.

Example 6

Patients in their twenties suffering from acne were divided into four groups, each consisting of 3 males and 3 females. Component A, B, the terpenoid isolated from component A or the (iso)scutellarein isolated from component B which were each dissolved in 1,3-butylene glycol at a concentration of 1% was applied to the diseased area of each person's face after washing with takalophene soap. The application was done daily on a twice-a-day basis and continued for a period of 2 months. The acne in each patient was diagnosed as being moderate and a mixture of comedones (primarily whiteheads), papules and pustules.

The therapeutic effects of the test samples were obvious; 60% of the treated cases were almost cured; 30% was half cured; and 10% showed a 30% reduction in severity. There was found no significant difference in efficacy among the test samples; the difference by sex was also insignificant.

Example 7

Among the diterpenoids to be used in the invention, (E)-8(17),12,14-labdatrien-18-oic acid may be extracted and isolated in pure form by the following procedure.


A powder of Thuja orientalis is mixed with about 5 volumes of n-hexane and the mixture is heated under reflux and filtered. The solvent in the filtrate is distilled off under vacuum and the residue is dissolved in 60% ethanol which is about twice the amount of the starting Thuja orientalis powder. The undissolved portion is filtered off and the solvent in the filtrate is distilled off under vacuum to yield a solid residue (component A).

This is not the sole procedure for extracting and fractionating component A and the n-hexane may be replaced by other solvents such as petroleum ether, petroleum benzine and benzene. The described procedure is efficient and achieves high yield.

Thus obtained component A is passed through an open silica gel column with a mixture of n-hexane and ethyl acetate being used as a developing solvent system. Following TLC on a thin layer coated with silver nitrate, the active spot containing the desired inhibitor was scraped and passed again through an open silica gel column to prepare a pure sample.

A flowchart of this process is set forth below in Table 1'.

Table 1'

55 Example 8

A substance having the 5 α -reductase inhibiting activity was isolated from component A as one having the most intense uv absorption and the sturcture of the thus isolated substance was characterized.

When a ^1H NMR spectrum was taken, similar quartet peaks were found at δ values of 6.8 and 6.3 whereas similar

triplet peaks occurred at δ values of 5.4 and 5.3. Since the integral was 1 at $\delta = 6.3$ and 5.4 and 0.7 at $\delta = 6.8$ and 5.3, two substances of similar structures having respective triplet and quartet peaks in pairs were assumed to be present in component A. To verify this assumption, component A was subjected to preparative TLC on a thin layer coated with silver nitrate, whereby the two substances could be isolated.

5 These substances were characterized for their structures by measuring ^1H and ^{13}C NMR spectra, mass spectrum, ir absorption spectrum, uv absorption spectrum and optical rotation; as a result, both substances were estimated to be 8(17), 12,14-labdatrien-19-oic acid having the labdane skeleton. In order to identify their stereostructures, a NOESY plot was taken for the protons in the ^1H NMR spectrum; in one compound, correlation was found between the 14-
10 position and each of the 15- and 12-positions and in the other compound, correlation was found between the 14-
position and each of the 15- and 16-positions; hence, the two compounds were estimated to be of an (E)- and a (Z)-
form, respectively. Similarly, an absorption occurred at 990 cm^{-1} and 770 cm^{-1} in the ir spectrum. Hence, the two com-
pounds were determined to be (E)- and (Z)-8(17),12,14-labdatrien-19-oic acid.

A crude enzyme solution for assaying the 5α -reductase inhibiting action was prepared according to the procedure already set forth in Table 2.

15 Using the thus prepared crude enzyme solution, the 5α -reductase inhibiting action was assayed by the method set forth in Table 7 under 2).

20

25

30

35

40

45

50


55

Table 7

1) Reaction fluid

| Ingredient | Amount of addition, ml | Final concentration, mmol/L |
|---|------------------------|-----------------------------|
| 0.28 mM testosterone (in 10% MeOH) | 0.25 | 0.07 |
| 50 mM Tris-HCl buffer solution (pH 7.0) | 0.10 | 5.0 |
| 50 mM NAPH solution | 0.25 | 5.0 |
| Sample (in 60% EOH) | 0.25 | - |
| Crude enzyme solution | 0.025 | - |
| Purified water | 0.325 | - |
| To make | 1.0 | |

2) Assay method



*For measuring A₀, the reaction fluid and dichloromethane were charged simultaneously and the mixture was immediately stirred without incubation. For measuring A₀ and A₂₀ on the control, the sample was subjected to reaction in 60% ethanol.

The extract of *Thuja orientalis* (component A), the trans-communic acid isolated from component A, flutamide and cyproterone were measured for their activity in inhibiting 5 α -reductase *in vitro* and the results are shown graphically in Fig. 2. The percent inhibition of 5 α -reductase was calculated by:

$$\left(1 - \frac{\text{exp. A0-A20}}{\text{cont. A0-A20}}\right) \times 100$$

Example 9

Patients in their twenties who were suffering from acne were divided into five groups each consisting of 3 males and 3 females and treated with a lotion of the following formula prepared in accordance with the invention.

Table 8

| | |
|---------------------|-----|
| Ethanol | 50% |
| 1,3-Butylene glycol | 20% |
| HCO-60 | 3% |
| Diterpene | 1% |
| Purified water | 26% |

The lotion was applied to the diseased part of a patient's face after washing with takallophene soap and the treatment was conducted daily on a twice-a-day basis for a period of 2 months. The acne in each patient was diagnosed as being moderate and a mixture of comedones (primarily whiteheads), papules and pustules.

The results were evaluated by the following criteria: 3, cured completely; 2, half cured; 1, cured 30%; 0, not cured. The highest score was 18 and the lowest score was 0.

Table 9

| Diterpenoid | Score | |
|--|-------|-------|
| | 1 mol | 2 mo. |
| Sample I | 8 | 18 |
| Sample II | 10 | 18 |
| Sample III | 9 | 18 |
| Flutamide | 4 | 8 |
| Water | 0 | 0 |
| Sample I: (E)-8(17),12,14-labdatrien-19-oic acid | | |
| Sample II: (E)-8(17),12,14-labdatriene | | |
| Sample III: (E)-8(17),12,14-labdatrien-19-ol | | |

The therapeutic effects of the three diterpenoids under test were obvious and there was no significant difference in efficacy among them. There was also found no significant difference by sex.

Another formula of acne curative may be as follows.

Table 10

| Ingredient | Percent by weight |
|--------------------------|----------------------|
| Trans-diterpene | 0.01 - 1.0 |
| Synthetic silica alumina | 1.0 - 3.0 |
| Takalophene | |
| Urea | 2.0 |
| Sodium salicylate | 0.2 |
| Solvent | to make 100 |

When the diterpene and takapherone were incorporated at respective concentrations of 0.1% and 3%, the formula as applied to patients suffering from moderate acne (aged 19 - 51; 13 males and 44 females) gave the following result after 4 months of application: 5 cases cured completely and 52 cases showed a pronounced effect as evidenced by the decrease in the number of eruptions to one third or less.

Example 10

Diterpenes of the invention were evaluated for their therapeutic effects on male pattern baldness in stage V. The curatives were prepared in accordance with the formula set forth in Table 11.

Table 11

| | |
|------------------|-----|
| Ethanol | 50% |
| Propylene glycol | 10% |
| HCO-60 | 3% |
| Diterpene | 1% |
| Purified water | 36% |

The curatives were applied to the bald area of male volunteers (aged 27 - 45) in five groups each consisting of 5 cases. The application was done daily on a twice-a-day basis and continued for 6 months. The therapeutic efficacy was evaluated by the following criteria based on the decrease in the area of the parietal alopecic lesion and the density of regrowing hairs: 10 (alopecic area decreased to 1/5 or less and hair density increased by 2/3 or more); 7 (alopecic area decreased to 1/3 or less and hair density increased by 1/3 or more); 4 (alopecic area decreased to 1/2 or less and hair density increased by 1/5 or more); 2 (alopecic area decreased by 20% and hair density increased by 10% or more); 1 (alopecic area hardly changed but hair density increased definitely); 0 (no change at all).

Table 12

| Diterpenoid | Score | | | | |
|--|-------|-------|-------|-------|-------|
| | 0 mo. | 1 mo. | 2 mo. | 4 mo. | 6 mo. |
| Sample I | 0 | 1 | 4 | 7 | 10 |
| Sample II | 0 | 1 | 4 | 7 | 10 |
| Sample III | 0 | 0 | 4 | 7 | 10 |
| Flutamide | 0 | 1 | 2 | 2 | 4 |
| Water | 0 | 0 | 0 | 0 | 0 |
| Sample I: (E)-8(17),12,14-labdatrien-19-oic acid | | | | | |
| Sample II: (E)-8(17),12,14-labdatriene | | | | | |
| Sample III: (E)-8(17),12,14-labdatrien-19-ol | | | | | |

The three diterpenes under test had no significant differences in therapeutic efficacy and they all proved to be definitely effective in curing male pattern baldness.

Example 13

An experiment was conducted on 5 hirsute male volunteers aged 25 - 48. The center of each straight leg was depilated with wax to create a lesion about 2 cm wide and 3 cm long. The depilated lesion on one inferior limb was treated with 50% ethanol and the lesion on the other inferior limb was treated with 0.1% trans-communic acid dissolved in 50% ethanol. The application was done daily on a twice-a-day basis for 3 consecutive months. The results were as follows.

Table 13

| Case | Control section | Test section |
|------|---|---|
| A | Regrowth of hair in the depilated area was indistinguishable from the hair density in the surrounding area. | No regrowth of hair in the depilated lesion |
| B | do. | do. |
| C | do. | Regrowth of a few hair |
| D | do. | No regrowth of hair |
| E | do. | do. |

Example 14

Five women (aged 20 - 35) suffering from idiopathic hirtuism were treated with 0.1% trans-communic acid in 50% ethanol that was applied daily to a wax depilated area of the right forearm on a twice-a-day basis. Depilation was repeated every other month until the end of the experiment. The overall results of the experiment are shown in Table 14 below.

Table 14

| Case | First measurement (before treatment) | | Sixth measurement | |
|------|--------------------------------------|---------------------|-------------------|---------------------|
| | Hair density | Hair length, mm | Hair density | Hair length, mm |
| A | thick | peaked at ca. 10 mm | sparse | peaked at ca. 10 mm |
| B | thick | peaked at ca. 6 mm | a few | ca. 1 mm |
| C | thick | peaked at ca. 10 mm | sparse | peaked at ca. 3 mm |
| D | thick | peaked at ca. 8 mm | a few | ca. 2 mm |
| E | thick | peaked at ca. 7 mm | a few | ca. 1 mm |

Measurements were conducted on the hairs attached to the cloth used for wax depilation.

Example 15

Seven-week old BALB/CA-nu/nu mice were transplanted with androgen-dependent human prostatic cancer strain HONDA beneath the dorsal skin and 6-week old BALB/CA-nu/nu mice were transplanted with androgen-dependent rat prostatic cancer strain R3327-G beneath the dorsal skin. When the respective tumors grew to a specified size, the animals were divided into test and control groups. The test groups were administered with suspensions of trans-communic acid and flutamide in 0.5% CMC. The control groups were administered with 0.5% CMC alone. The drugs and the vehicle were administered perorally via an oral probe. The administration was repeated daily for 28 consecutive days on a once-a-day basis. The tumor volume (mm^3) was calculated by the formula of major axis (mm) \times the square of minor axis (mm^2)/2. The drugs were rated as "effective" when they could control the growth of tumors to such a degree that the tumor volume was no more than half the volume of tumors in the control groups and when the difference was found to be statistically significant in the student's t test ($p < 0.05$).

Strain HONDA decreased in size when the mice carrying that cancer were castrated. Trans-communic acid could control the growth of this cancer significantly in a dose-dependent manner. The positive control flutamide was also effective in tumor control but its efficacy was considerably weaker than that of trans-communic acid and the tumor size of the group administered with 20 mg/kg of trans-communic acid was almost comparable to that of the group administered with 200 mg/kg of flutamide.

The growth of cancer strain R3327-G was not controlled in castrated mice when they were administered 25 mg of testosterone enanthate per head concurrently with the cancer transplantation. Even in such mice, trans-communic acid could effectively control the growth of cancer in a dose-dependent manner and its efficacy was considerably stronger than that of flutamide.

Claims

1. A non-steroidal curative of diseases caused by the overactivity of 5α -reductase or the hypersecretion of androgens, which contains as an active ingredient a fractionated extract of Thuja orientalis that contains a 5α -reductase inhibitor.
2. A curative according to claim 1, wherein the 5α -reductase inhibitor in the fractionated extract of Thuja orientalis is a terpenoid.
3. A curative according to claim 1, wherein the 5α -reductase inhibitor in the fractionated extract of Thuja orientalis is a flavonoid.
4. A curative according to claim 3, wherein the flavonoid is (iso)scutellarein.
5. A curative of diseases caused by the overactivity of 5α -reductase or the hypersecretion of androgens, which contains at least one diterpene that has a double bond in the 12- and 14-positions, with the double bond in the 12-position taking the configuration E.
6. A curative according to claim 1 or 5, wherein the disease caused by the overactivity of 5α -reductase or the hyper-

secretion of androgens is male pattern baldness, androgenetic alopecia, hirsutism, acne, prostatomegaly or cancer of the prostate.

5

10

15

20

25

30

35

40

45

50

55

Fig.1





Fig. 2



(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 747 048 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:

15.04.1998 Bulletin 1998/16

(51) Int. Cl.⁶: **A61K 31/19**, A61K 31/045,

A61K 35/78, A61K 31/015,

A61K 7/06, A61K 7/48

(43) Date of publication A2:

11.12.1996 Bulletin 1996/50

(21) Application number: 96109269.9

(22) Date of filing: 10.06.1996

(84) Designated Contracting States:

DE FR GB

(30) Priority: 09.06.1995 JP 143504/95

29.02.1996 JP 43029/96

(71) Applicant:

Kabushiki Kaisha Yakurigaku Chuo Kenkyusho
Tokyo 157 (JP)

(72) Inventors:

• Takahashi, Hidehiko
Tokyo 157 (JP)

• Hara, Susumu,

c/o K.K. Yakurigaku Chuo Kenkyusho
Tokyo 157 (JP)

• Matsui, Rieko,

c/o K.K. Yakurigaku Chuo Kenkyusho
Tokyo 157 (JP)

(74) Representative:

Henkel, Feller, Hänzel

Möhlstrasse 37

81675 München (DE)

(54) **Diterpenes and flavonoids as 5-alpha-reductase inhibitors**

(57) Strong 5 α -reductase inhibitors are extracted and fractionated from Thuja orientalis and other similar crude drugs or they may be purified as diterpenes in isolated form. The inhibitors are used either on their own or as active ingredients of therapeutics in the treatment of diseases caused by the overactivity of 5 α -reductase or the hypersecretion of androgens, such as male pattern baldness, androgenetic alopecia, hirsutism, acne, prostatomegaly and cancer of the prostate.

EP 0 747 048 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 10 9269

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|---|---|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.Cl.6) |
| X | PATENT ABSTRACTS OF JAPAN vol. 13, no. 171 (C-588), 24 April 1989 & JP 64 083125 A (ICHIMARU PHARCOS CO LTD.), 6 January 1989, * abstract * | 1,6 | A61K31/19 A61K31/045 A61K35/78 A61K31/015 A61K7/06 A61K7/48 |
| X | --- DATABASE WPI Section Ch, Week 9515 Derwent Publications Ltd., London, GB; Class D21, Page e34, AN 95-110518 XP002043073 & JP 07 033 627 A (SERESUKOSUMEPURAN KK) , 3 February 1995 * abstract * | 1,6 | |
| X | --- PATENT ABSTRACTS OF JAPAN vol. 13, no. 308 (C-617), 14 July 1989 & JP 01 096126 A (KAO CORP), 14 April 1989, * abstract * | 3,6 | |
| A | --- PERRY, N.B. ET AL: "Antitumour lignans and cytotoxic resin acids from a New Zealand gymnosperm, Libocedrus plumosa" PHYTOMEDICINE, vol. 1, no. 3, 1994, pages 233-237, XP002043069 * abstract * * page 236, left-hand column, line 33-42 * | 5,6 | TECHNICAL FIELDS SEARCHED (Int.Cl.6) A61K |
| A | --- SHARMA S ET AL: "Diterpenoids from Thuja orientalis leaves" FITOTERAPIA, 64 (5). 1993. 476-477., XP002043070 * the whole document * | 1,2 | |
| --- -/-- | | | |
| -The present search report has been drawn up for all claims | | | |
| Place of search THE HAGUE | | Date of completion of the search 9 October 1997 | Examiner MAIR J. |
| CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document | | T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document | |

EPO FORM 1503 03.82 (P04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 10 9269

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|--|---|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.Cl.6) |
| A | KHABIR M ET AL: "PHENOLIC CONSTITUENTS OF THUJA-ORIENTALIS" CURR SCI (BANGALORE), 54 (22). 1985 (RECD. 1986). 1180-1181., XP002043071 * the whole document * | 1,2 | |
| A | KOMODA Y: "Isolation of flavonoids from Populus nigra as delta 4-3-ketosteroid (5 alpha) reductase inhibitors." CHEM PHARM BULL (TOKYO), NOV 1989, 37 (11) P3128-30, JAPAN, XP002043072 * the whole document * | 1,3,4 | |
| | | | TECHNICAL FIELDS SEARCHED (Int.Cl.6) |
| <p>-The present search report has been drawn up for all claims</p> | | | |
| Place of search THE HAGUE | | Date of completion of the search 9 October 1997 | Examiner MAIR J. |
| <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p> | | | |

EPO FORM 1503 03.82 (P04C01)



European Patent
Office

Application Number

EP 96 10 9269

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B + C sheet

☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-4 & 6 (all partially)



European Patent Office

96109269.9 - B -

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions, or groups of inventions, namely:

SUBJECT SEARCHED:

1. YES Claims 1-4 & 6 (all partially) An agent comprising a fractionated extract of *Thuja orientalis* and its use for the treatment of diseases caused by overactivity of 5 α -reductase.
2. NO Claims 1-4 & 6 (all partially) An agent comprising a fractionated extract of *Thuja orientalis* and its use for the treatment of diseases caused by the hypersecretion of androgens.
3. NO Claims 5 & 6 (partially) An agent comprising a diterpene that has "a double bond in the 12- and 14- positions, with the double bond in the 12- position taking the E configuration" and its use for the treatment of diseases caused by overactivity of 5 α -reductase.
4. NO Claims 5 & 6 (partially) An agent comprising a diterpene that has "a double bond in the 12- and 14- positions, with the double bond in the 12- position taking the E configuration" and its use for the treatment of diseases caused by the hypersecretion of androgens.



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number

EP 96 10 9269

This search report has not been established in respect of certain claims, because they relate to subject matter that does not comply with the provisions of the European Patent Convention, namely:

Claim(s) searched completely:

0

Claim(s) searched incompletely:

1-6

Reason for the limitation of the search:

"diseases caused by the overactivity of 5 alpha reductase or the hypersecretion of androgens" are not clear definitions of a therapeutic application because it is not known which diseases do or do not fall under these definitions.

The definition of the compounds in claim 5 as "...diterpene that has a double bond in the 12- and 14- positions, with the double bond in the 12-position taking the configuration E" is not clear and concise and the nomenclature used is non-standard. It is not clear which group of compounds is intended.

For these reasons the search has been restricted to the specifically mentioned diseases and compounds.

THIS PAGE BLANK (USPTO)